Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114.

TMC114 (darunavir) is a promising clinical inhibitor of HIV-1 protease (PR) for treatment of drug resistant HIV/AIDS. We report the ultra-high 0.84 A resolution crystal structure of the TMC114 complex with PR containing the drug-resistant mutation V32I (PR(V32I)), and the 1.22 A resolution structure of a complex with PR(M46L). These structures show TMC114 bound at two distinct sites, one in the active-site cavity and the second on the surface of one of the flexible flaps in the PR dimer. Remarkably, TMC114 binds at these two sites simultaneously in two diastereomers related by inversion of the sulfonamide nitrogen. Moreover, the flap site is shaped to accommodate the diastereomer with the S-enantiomeric nitrogen rather than the one with the R-enantiomeric nitrogen. The existence of the second binding site and two diastereomers suggest a mechanism for the high effectiveness of TMC114 on drug-resistant HIV and the potential design of new inhibitors.

[1]  Irene T Weber,et al.  Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 Å resolution crystal structures of HIV‐1 protease mutants with substrate analogs , 2005, The FEBS journal.

[2]  Peter Briggs,et al.  A graphical user interface to the CCP4 program suite. , 2003, Acta crystallographica. Section D, Biological crystallography.

[3]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[4]  Thomas D. Wu,et al.  Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments , 2003, Journal of Virology.

[5]  R F Schinazi,et al.  Polyoxometalate HIV-1 protease inhibitors. A new mode of protease inhibition. , 2001, Journal of the American Chemical Society.

[6]  C. Hutchison,et al.  Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Celia A Schiffer,et al.  Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. , 2005, Journal of medicinal chemistry.

[8]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[9]  G. Sheldrick,et al.  SHELXL: high-resolution refinement. , 1997, Methods in enzymology.

[10]  G. Marius Clore,et al.  Autoprocessing of HIV-1 protease is tightly coupled to protein folding , 1999, Nature Structural Biology.

[11]  Brendan A. Larder,et al.  Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples , 2000, AIDS.

[12]  J. Konvalinka,et al.  Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex. , 2004, Acta crystallographica. Section D, Biological crystallography.

[13]  Dirk Jochmans,et al.  TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates , 2005, Antimicrobial Agents and Chemotherapy.

[14]  E. Freire,et al.  Adaptive inhibitors of the HIV-1 protease. , 2005, Progress in biophysics and molecular biology.

[15]  Gautam R. Desiraju,et al.  The Weak Hydrogen Bond: In Structural Chemistry and Biology , 1999 .

[16]  Irene T Weber,et al.  Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. , 2004, European journal of biochemistry.

[17]  Irene T. Weber,et al.  Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro , 2003, Antimicrobial Agents and Chemotherapy.

[18]  B. Greenberg,et al.  The Mechanism of γ-Secretase , 2003, Journal of Biological Chemistry.

[19]  J. Tözsér,et al.  Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease. , 2005, Bioorganic & medicinal chemistry letters.

[20]  C. Alsenoy,et al.  Ab initio calculation of the interaction energy in the P2 binding pocket of HIV-1 protease , 2005 .

[21]  R M Esnouf,et al.  Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. , 1999, Acta crystallographica. Section D, Biological crystallography.

[22]  J. Louis,et al.  Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. , 2000, European journal of biochemistry.

[23]  Celia A. Schiffer,et al.  Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor , 2004, Journal of Virology.

[24]  Joseph Quinn,et al.  Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults , 2001, AIDS.

[25]  D. Walters,et al.  Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. , 1998, Bioorganic & medicinal chemistry letters.

[26]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[27]  R. L. Rowley,et al.  Determination of an ethane intermolecular potential model for use in molecular simulations from ab initio calculations , 1999 .

[28]  Amalio Telenti,et al.  Update of the drug resistance mutations in HIV-1: Fall 2005. , 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[29]  G. Desiraju,et al.  NH…O, OH…O, and CH…O hydrogen bonds in protein–ligand complexes: Strong and weak interactions in molecular recognition , 2003, Proteins.

[30]  Arun K. Ghosh,et al.  Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. , 2006, Journal of medicinal chemistry.

[31]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[32]  E. Clercq.  New approaches toward anti-HIV chemotherapy. , 2005 .

[33]  A Wlodawer,et al.  Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. , 1998, Annual review of biophysics and biomolecular structure.

[34]  Irene T Weber,et al.  High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. , 2004, Journal of molecular biology.

[35]  Paul A Keller,et al.  Control of hepatitis C: a medicinal chemistry perspective. , 2005, Journal of medicinal chemistry.

[36]  J. Mellors,et al.  3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine , 2000, Annals of Internal Medicine.